Home > Formulary : Adult > Recent Decisions > 2013 >
Decisions 23rd July 2013
Recent JFG Decisions
At the meeting on the 23rd July 2013 the following decisions / changes to the formulary were agreed:
New Drug Requests
Approved
Mirabegron
- NICE TA 290 – will be included on formulary in line with implementation of NICE TAs (90 days from publication) – TLS Blue after patient has tried bladder training and two antimuscarinic drugs.
Denosumab for men
- Clinically appropriate (clinical effectiveness and equity of access) for inclusion in formulary in line with TA 204. TLS amber. SCP to be updated.
Voractiv® (rifampicin, isoniazid, pyrazinamide and ethambutol)
- Added to formulary - useful addition to reduce the pill burden, TLS Red.
Dermovate® with 40% polypropylene
- Added to formulary due to its place in therapy relative to available treatments for use in severe hyperkeratotic psoriasis and eczema of the palms and / or soles for 4 weeks. TLS Red specialist consultant use only.
Not approved, More information requested
Ozurdex® (dexamethasone intravitreal implant)
- Clinically appropriate to add to formulary for licenced indication (one implant only) but financial modelling not submitted to show a cost neutral or cost saving position. The JFG was unable to approve the application at this time.
Lixisenatide
- Clinical non-inferiority to exenatide was agreed however superiority data was lacking. The JFG would like to further explore the cost-effectiveness of lixisenatide. The application was not approved at this time.
Specialised Commissioning
None
Other Decisions
None